1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Propanc Biopharma, Inc.

Propanc Biopharma, Inc.

PPCBD
Propanc Biopharma, Inc.US flagOther OTC
5.68
USD
+0.68
- -
87,307.00Market Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-2,553.34
-1,427.82
-1,706,377
-1,882,070.4
-874,166.67
-76,512.55
-5,758,369
-18,374.9
-668.19
-886,029
-665,141.5
-1,284.78
-14.85
-2.07
Free Cash Flow per Basic Share
-227.69
-389.75
-715,190
-902,275.6
-227,848.44
-23,670.05
-2,062,911
-7,168.95
-377.73
-478,768
-276,312.75
-659.93
-0.1
-0.46
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-29,473.8
-30,086.46
-10,309,114.5
-6,074,621.8
-4,248,771.67
-492,202.01
-51,040,079
-216,207.41
-19,190.44
-20,519,217.67
-16,169,270
-47,070.02
-31.65
-15.88
Tangible Book Value per Share
-1,402.61
-2,423.95
-1,529,258
-514,058.6
-605,194.56
-73,444.78
-4,306,236
-14,133.43
-1,013.38
-1,009,549.67
-779,294.75
-2,666.94
3.5
1.11
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
9
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-1
-3
-9
-8
-7
-6
-5
-2
-3
-3
-2
-59
-18
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-1
-1
-3
-3
-5
-7
-4
-4
-3
-3
-3
-4
3
5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-1
-1
-3
-3
-5
-7
-4
-4
-3
-3
-3
-4
14
11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
1
1
Shares Outstanding
1
1
1
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
9
8
8
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
3
Payables & Accruals
2
2
2
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-39.23%
-92.17%
-467.98%
Free Cash Flow
4.37%
-21.56%
-56.67%
Net Income, GAAP
319.2%
615.81%
3,136.6%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-38,985.11
-24,349.33
-7,215.07
- -
-1,284.78
2025
-287.82
-32.23
-12.5
- -
-14.85
2026
-0.39
-0.23
-7.09
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
James Nathanielsz
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
302, 6 Butler Street Camberwell VIC Australia 3124
IPO Date
Nov 12, 2012
Website
propanc.com
Similar Companies
ASLAN Pharmaceuticals Limited (ASLN)
Tryp Therapeutics Inc. (TRYP.CN)
ORIC Pharmaceuticals, Inc. (ORIC)
ToolGen Inc (199800.KS)
OncoVista Innovative Therapies, Inc. (OVIT)
Amicus Therapeutics, Inc. (FOLD)
Business
Propanc Biopharma, Inc. Propanc Biopharma, Inc. (Nasdaq: PPCB) is a clinical-stage biopharmaceutical company that develops novel proenzyme-based therapies to treat recurrent and metastatic solid tumors, primarily targeting pancreatic, ovarian, and colorectal cancers. The company's lead product candidate, PRP, comprises a patented formulation of two proenzymes in a synergistic ratio that induces cancer cell differentiation, inhibits tumor growth and metastasis, suppresses cancer stem cells, blocks angiogenesis, and promotes cell death; its pipeline also includes POP1 in research and Rec-PRP, a fully synthetic recombinant version advancing to preclinical development for enhanced stability and scalability. Headquartered in Camberwell, Australia, and founded in 2007, Propanc operates globally with research collaborations in Spain, including ongoing joint programs with the Universities of Jaén and Granada on POP1 and GMP manufacturing partnerships such as with Q Biologicals. Recent developments include a November 2025 securities purchase agreement with Hexstone Capital LLC for up to $100 million in convertible preferred stock to fund digital asset acquisitions and accelerate R&D, with an initial $1 million tranche received; a closed underwritten public offering of 1,000,000 shares at $4.00 raising $4 million gross proceeds; Nasdaq uplisting with trading commencing August 15, 2025; advancement of PRP toward a Phase 1b first-in-human trial in 30-40 patients with advanced solid tumors at Peter Mac Cancer Center in 2026, supported by GMP scale-up achieving over 95% purity; and negotiation of a 12-month extension for the POP1 program yielding new patent filings on reduced tumorigenicity in gemcitabine-resistant pancreatic cancer.

Company News

APIChat

  • headlinesoftoday.com

    Propanc Biopharma Announces Strategic Pharma Partnering Initiative

  • headlinesoftoday.com

    Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe